Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Python cancer-free after ‘world-first’ treatment
Surgeons removed part of the snake's jaw before performing electrochemotherapy.
A tumour destroyed part of her jaw.

A reticulated python is cancer-free after becoming the first snake to have a pioneering human cancer therapy.
 
The 15-foot snake, named Jodie Foster, underwent electrochemotherapy – a treatment usually used for humans.
 
Jodie was given the treatment when the cancerous tumour returned after a surgical procedure. The tumour had invaded her jawbone, causing it to become diseased.
 
Since Jodie was too big for one operating table, her veterinary team had to improvise. The python was anaesthetised in her habitat, then carried to the veterinary centre.
 
Meanwhile, at the veterinary centre, the team had put two operating tables together into a ’double bed’, complete with heated blankets and warmed air to maintain her temperature.
 
Ian Ashpole, veterinary officer at Chester Zoo, began by surgically removing the tumorous mass. He then performed a hemi-mandibulectomy to remove part of Jodie’s diseased jawbone.
 
They then begun electrochemotherapy, which targeted any remaining cancerous cells.
 
The procedure combined a cancer drug, bleomycin, with a series of carefully controlled electrical pulses directed at the tumour site.
 
The pulses make the cancer cells temporarily more permeable, which permits the bleomycin to enter more effectively. This means that lower doses of chemotherapy can be used, often in a single procedure.
 
Following the procedure, Jodie has fully recovered and has been declared cancer-free. Even with part of her jawbone removed, she is able to strike, grip and swallow food without difficulty.
 
Dr Ashpole said: “Seeing her back to her normal bright and feisty self has been incredibly rewarding. A few months ago, we genuinely didn't know whether she'd survive. Now she's eating normally, exploring her habitat and behaving exactly as we'd hope.”
 
Jose Alvarez Picornell, from the Department of Small Animal Clinical Science at University of Liverpool, said: "Electrochemotherapy is an emerging treatment, and this was the first time it had been used in a snake The success of this treatment is a testament to the power of collaboration. By working closely with Ian, we were able to develop a plan that not only benefited Jodie Foster but will also contribute to the wider veterinary community.
 
“We will be formally publishing details of the procedure so that veterinary colleagues around the world can learn from and build upon our approach. This has been a very special career highlight for me, and a fantastic opportunity to expand the work we do within the Department to support high-quality veterinary and translational research.”
 
Image © Chester Zoo

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.